Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in Montfermeil – page 36

3 423 clinical trials in Montfermeil, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Montfermeil at a glance
3 423
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 423 trials in Montfermeil

Open in trial search

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

MELAS syndrome+2

Recruiting

A study testing sonlicromanol in adults with genetically confirmed mitochondrial DNA 3243A>G variant causing mitochondrial disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Sonlicromanol
  • Sponsor:Khondrion B.V.

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Syndax Pharmaceuticals Inc.

Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ivonescimab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

A study of RO7268489 added to ocrelizumab compared to placebo in adults with progressive multiple sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Gustave Roussy

Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RP2
  • Sponsor:Replimune Inc.

Ovarian cancer

Recruiting

A Study of Mirvetuximab Soravtansine, Carboplatin, and Bevacizumab in Adults with Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Testing Treprostinil Palmitil Inhalation Powder for Improving Exercise Ability in Patients with Pulmonary Hypertension Related to Interstitial Lung Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study testing gene therapy with DREAM01 and imatinib for patients with severe sickle cell disease to improve red blood cell production

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:DREAM01
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in France

The busiest research cities in the country

All 376 cities in France

Clinical research in Montfermeil

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on acute myocarditis treatment and cardiac arrhythmia management. Research includes evaluation of corticosteroid therapy for improving left ventricular function and investigating preventive measures for premature ventricular complexes.

  • Myocarditis Treatment Optimization
  • Cardiac Function Management
  • Giant Cell Arteritis Studies

These trials aim to enhance treatment outcomes for patients with various cardiac conditions.

02 Respiratory Medicine

Advanced research in severe asthma management, exploring new biological therapies and treatment optimization strategies. Studies focus on comparing different therapeutic approaches for patients with eosinophilic phenotypes.

  • Asthma Biologics Evaluation
  • Treatment Duration Assessment
  • Therapeutic Monitoring

Investigations aim to improve long-term outcomes for patients with severe respiratory conditions.

03 Inflammatory Conditions

Comprehensive studies examining treatments for ulcerative colitis, sarcoidosis, and inflammatory eye conditions. Research includes innovative monitoring approaches and medication optimization.

  • Gastrointestinal Disorders
  • Autoimmune Conditions
  • Novel Treatment Strategies

Focus on improving patient outcomes through targeted therapies and personalized treatment approaches.

04 Rheumatology and Joint Health

Investigating innovative treatments for knee osteoarthritis and gout, particularly in patients with complex medical conditions. Studies explore new interventional procedures and medication alternatives.

  • Joint Disease Management
  • Pain Control Studies
  • Minimally Invasive Treatments

Research aims to enhance quality of life for patients with chronic joint conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.